1 |
Martin GS,Mannino DM,Eaton S,et al. The Epidemiology of sepsis in the United States from 1979 through 2000 [J]. N Engl J Med,2003,348(16):1546-1554.
|
2 |
Ma J,Liao XL,Luo B,et al. Role of apolipoprotein A-I in protecting against endotoxin toxicity[J]. Acta Biochim Biophys Sinica,2004,36(6):419-424.
|
3 |
Gupta H,Dai L,Datta G,et al. Inhibition of lipopolysaccharideinduced inflammatory responses by an apolipoprotein AI mimetic peptide[J].Circ Res,2005,97(3):236-243.
|
4 |
Henning MF,Herlax V,Bakas L. Contribution of the C-terminal end of apolipoprotein AI to neutralization of lipopolysaccharide endotoxic effect[J].Innate Immun,2011,17(3):327-337.
|
5 |
Li Y,Dong JB,Wu MP. Human ApoA-Ⅰ overexpression diminishes LPS-induced systemic inflammation and multiple organ damage in mice[J].Eur J Pharmacol,2008,590(1-3):417-422.
|
6 |
Yan Y,Li Y,Lou B,et al. Beneficial effects of ApoA-Ⅰ on LPSinduced acute lung injury and endotoxemia in mice[J]. Life Sci,2006,79(2):210-215.
|
7 |
Wang L,Chen WZ,Wu MP.Apolipoprotein A-I inhibits chemotaxis,adhesion,activation of THP-l cells and improves the plasma HDL inflammatory index[J].Cytokine,2010,49(2):194-200.
|
8 |
Barlage S,Frohlich D,Bottcher A,et al. ApoE-containing high density lipoproteins and phospholipid transferprotein activity increase in patients with a systemic inflammatory response[J]. J Lipid Res,2001,42(2):281-290.
|
9 |
Berbée JF,vander Hoogt CC,Kleemann R,et al.Apolipoprotein C-I stimulates the response to lipopolysaccharide and reduces mortality in gram-negative sepsis[J].FASEB J,2006,20(12):2162-2164.
|
10 |
Berbée JF,van der Hoogt CC,Sundararaman D,et al. Severe hypertriglyceridemia in human APOC-I transgenic mice is caused by apoC-I-induced inhibition of LPL [J]. J Lipid Res,2005,46(2):2 9 7-3 0 4.
|
11 |
Conde-Knape K,Bensadoun A,Sobel JH,et al. Overexpression of apoC-I in apoE-null mice: severe hypertriglyceridemia due to inhibition of hepatic lipase[J].J Lipid Res,2002,43(12):2136-2145.
|
12 |
Shachter NS. Apolipoproteins C-I and C-Ⅲ as important modulators of lipoprotein metabolism[J].Curr Opin Lipidol,2001,12(3):297-304.
|
13 |
Berbée JF,Coomans CP,Westerterp M,et al. Apolipoprotein CI enhances the biological response to LPS via the CD14/TLR4 pathway by LPS-binding elements in both its N-and C-terminal helix[J]. J Lipid Res,2010,51(7):1943-1952.
|
14 |
Fu P,Wang AM,He LY,et al. Elevated serum ApoE levels are associated with bacterial infections in pediatric patients[J].J Microbiol Immunol Infect,2014,47(2):122-129.
|
15 |
Li L,Thompson PA,Kitchens RL. Infection induces a positive acute phase apolipoprotein E response from a negative acute phase gene:role of hepatic LDL receptors[J]. 2008,J Lipid Res,2008,49(8):1 7 8 2-1 7 9 3.
|
16 |
Wang C,Wang Y,Wang A,et al.The diagnostic value of apolipoprotein E in pediatric patients with invasive bacterial infections[J]. Clin Biochem,2012,45(3):215-218.
|
17 |
Zhang HL,Wu LM,Wu J. Cross-talk between Apolipoprotein E and cytokines[J].Mediators Inflamm,2011,2011:949072.
|
18 |
Kattan OM,Kasravi FB,Elford EL,et al. Apolipoprotein E-mediated immune regulation in sepsis[J].Immunology,2008,181(2):1399-1408.
|
19 |
van den Elzen P,Garg S,Leon L,et al. Apolipoprotein-mediated pathways of lipid antigen presentation[J]. Nature,2005,437(7060):9 0 6-91 0.
|
20 |
Kelley I. Chuang,Briana Leung,Nancy Hsu,et al. Heparin protects against septic mortality via apoE-antagonism[J]. American J Surg,2011,202(3):325-335.
|
21 |
Kumaraswamy SB,Linder A,Akesson P,et al. Decreased plasma concentrations of apolipoprotein M in sepsis and systemic inflammatory response syndromes[J]. Crit Care,2012,16(2):11 93-1 2 0 3.
|
22 |
石岩.严重脓毒症发病机制新认识[J].中国实用外科杂志,2012,32(11):956-958.
|
23 |
张柳,安友仲.中国危重病急救医学[J].2011,23(8):509-511.
|
24 |
Gräler MH. The role of sphingosine 1-phosphate in immunity and sepsis[J].Am J Clin Exp Immunol,2012,1(2):90-100.
|
25 |
Obinata H,Hla T. Sphingosine 1-phosphate in coagulation and inflammation[J].Semin Immunopathol[J].2012,34(1):73-91.
|
26 |
Camerer E,Regard JB,Cornelissen I,et al. Sphingosine-1-phosphate in the plasma compartment regulates basal and inflammation-induced vascular leak in mice[J].J Clin Invest,2009,119(7):1871-1879.
|
27 |
Sanchez T,Skoura A,Wu MT,et al.Timothy Hlalnduction of vascular permeability by the sphingosine-l-phosphate receptor-2 (S1P2R)and its downstream effectors ROCK and PTEN[J]. Arterioscler Thromb Vasc Biol,2007,27(6):1312-1318.
|
28 |
Sammani S,Moreno-Vinasco L,Mirzapoiazova T,et al. Differential effects of SIP receptors on airway and vascular barrier function in the murine lung[J].Am J Respir Cell Mol Biol,2010,43(4):394-402.
|
29 |
Zhang G,Xu S,Qian Y,et al. Sphingosine-l-phosphate prevents permeability increases via activation of endothelial sphingosinel-phosphate receptor 1 in rat venules[J]. Am J Physiol Heart Circ Physiol,2010,299(5):H1494-1504.
|
30 |
Singleton PA,Moreno-Vinasco L,Sammani S,et al.Attenuation of vascular permeability by methylaltrexone role of mOP-R and S 1 P3 transactivation[J]. Am J Respirat Cell Mol Biol[J]. 2007,37(2):2 2 2-2 3 1.
|
31 |
Shikata Y,Birukov KG,Garcia JG. SIP induces FA remodeling in human pulmonary endothelial cells: role of Rac,GIT1,FAK,and paxillin[J].JAppl Physiol(1985),2003,94(3):1193-1203.
|
32 |
Blaho VA,Hla T.Regulation of mammalian physiology,development,and disease by the sphingosine l-phosphate and lysophosphatidic acid receptors[J].Chem Rev,2011,111(10):6299-6320.
|